P 3 Therapeutics key facts
as of Oct 2026- Developer of novel anti-inflammatory drugs designed to address unmet needs in treating Spondyloarthritis.
- P 3 Therapeutics is valued at approximately $5.4M as of Oct 2026 (last reported valuation).
- It has raised $110K.
- Notable investors include Vesna Deep Tech Fund, SEE UP Accelerator.
- Status: Privately Held (backing).
P 3 Therapeutics's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch P 3 Therapeutics: the Monday email on marks, rounds and moves
P 3 Therapeutics funding rounds
No funding rounds for P 3 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs P 3 Therapeutics
2P 3 Therapeutics valuation
P 3 Therapeutics's last reported valuation was $5.4 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
P 3 Therapeutics investors
2 investors are on record for P 3 Therapeutics, including Vesna Deep Tech Fund and SEE UP Accelerator.
About P 3 Therapeutics
Developer of novel anti-inflammatory drugs designed to address unmet needs in treating Spondyloarthritis. The company's proprietary technology activates three anti-inflammatory targets while leveraging AI-driven "scaffold hopping" and generative AI for lead optimization, enabling medical professionals to provide treatment for chronic immune-mediated inflammatory disorders.
- Sector
- Healthcare
- HQ
- Zagreb, Croatia
- Founded
- 2024
- Employees
- 2
- Website
- p3therapeutics.eu/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.